Allele and genotype frequencies of Cytochrome P450 2B6 gene in a Mongolian population

Drug Metabolism and Disposition

Volumn 37, Issue 10, 2009, Pages 1991-1993

  Davaalkham, Jagdagsuren ^a   Hayashida, Tsunefusa ^a   Tsuchiya, Kiyoto ^a   Gatanaga, Hiroyuki ^a   Nyamkhuu, Dulmaa ^b   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b Ministry of Health   (Mongolia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ;

AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CHINESE; CONTROLLED STUDY; DRUG METABOLISM; GENE FREQUENCY; GENOTYPE; GINSENG; HAPLOTYPE; HUMAN; JAPANESE; MONGOLIA; NORMAL HUMAN; POPULATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VOLUNTEER;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BENZOXAZINES; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; GENOTYPE; HUMANS; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION GROUPS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70349295980     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.027755     Document Type: Article

References (20)

1. Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173. (Pubitemid 37372638)
2. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, et al. (2007) Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 45:1230-1237. (Pubitemid 47580326)
3. Guan S, Huang M, Li X, Chen X, Chan E, and Zhou SF (2006) Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm Res 23:1983-1990.
4. Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, and Zanger UM (2008) Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 325:284-292.
5. Hoffman SM, Nelson DR, and Keeney DS (2001) Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 11:687-698. (Pubitemid 33078238)
6. Jacob RM, Johnstone EC, Neville MJ, and Walton RT (2004) Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin Chem 50:1372-1377.
7. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mürdter TE, Roots I, and Brockmöller J (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619-626. (Pubitemid 37311148)
8. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, and Zanger UM (2005) Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15:861-873. (Pubitemid 41666768)
9. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415. (Pubitemid 32656581)
10. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, Schwab M, and Zanger UM (2004) Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 311:34-43. (Pubitemid 39287781)
11. Miksys S, Lerman C, Shields PG, Mash DC, and Tyndale RF (2003) Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45:122-132. (Pubitemid 36700458)
12. Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP, and Shimada T (1993) Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metab Dispos 21:1048-1056. (Pubitemid 23348341)
13. Porter TD (2004) Jud Coon: 35 years of P450 research, a synopsis of P450 history. Drug Metab Dispos 32:1-6.
14. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
15. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Décosterd L, Blievernicht J, Saussele T, Günthard HF, Schwab M, et al. (2007) Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 81:557-566. (Pubitemid 46454205)
16. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, and Oka S (2004) Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322-1326. (Pubitemid 38759555)
17. Wang J, Sonnerborg A, Rane A, Josephson F, Lundgren S, and Stahle L (2006) Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmocogenet Genomics 16:191-198. (Pubitemid 43312581)
18. Wang H and Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598-610.
19. Zanger UM and Hofmann MH (2008) Polymorphic cytochromes P450 CYP2B6 and CYP2D6: recent advances on single nucleotide polymorphisms affecting splicing. Acta Chim Slov 5:38-44.
20. Zukunft J, Lang T, Richter T, Hirsch-Ernst KI, Nussler AK, Klein K, Schwab M, Eichelbaum M, and Zanger UM (2005) A natural CYP2B6 TATA box polymorphism (-82T→C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 67: 1772-1782. (Pubitemid 40594179)